A new non-melanoma skin cancer (NMSC) treatment is being trialled in Australia for efficacy and comfort, quality of life and cosmetic outcomes for patients. “Australia has the highest incidence of NMSCs in the world, so it is imperative that we investigate new treatment options and continue to improve patient outcomes,” Siddhartha Baxi, a researcher of the study, said. Non-melanoma cancers-the less serious form of skin cancer-currently account for about 99 percent of skin cancers diagnosed each year, with the Cancer Council predicting that around two in three Australians will be diagnosed with skin cancer before the age of 70. The international EPIC-Skin clinical study led by OncoBeta GmbH will be testing the company’s Rhenium-SCT, a radioactive paste that kills cancer cells when applied by doctors to the affected area. Two hundred Australian patients will be treated with Rhenium-SCT and monitored over the next two years, and as a part of …